HIGHLIGHTS
- who: August and colleagues from the The University of Tennessee, United States have published the paper: Dapagli ozin protects against nonalcoholic steatohepatitis in db/db mice, in the Journal: (JOURNAL)
- what: The authors used db/db mice with NAFLD to evaluate the long-term action of dapagliflozin on the liver. The motivation of this study was to determine whether dapagliflozin could improve NASH db/db mice, which are leptin receptor deficient and have obesity, hyperglycemia, hyperinsulinemia, insulin resistance, and fatty liver, widely used as an animal model of NAFLD (Santhekadur et_al, 2018). Either FXR agonists . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.